Takara Bio (TSE:4974) Total Liabilities: 円29,692 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4974 Takara Bio Inc TSE:4974
50 GF Score
Price 円1,144.00
GF Value 円862.14
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Takara Bio Total Liabilities?

Takara Bio TSE:4974 50 Total Liabilities is 円29,692 Mil as of Mar. 2026. GuruFocus rates TSE:4974 with a GF Score™ of 50/100 and a GF Value™ of 円862.14 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Takara Bio's Total Liabilities for the quarter that ended in Mar. 2026 was 円29,692 Mil.

Takara Bio's quarterly Total Liabilities declined from Sep. 2025 (円29,207.00 Mil) to Dec. 2025 (円29,153.00 Mil) but then increased from Dec. 2025 (円29,153.00 Mil) to Mar. 2026 (円29,692.00 Mil).

Takara Bio's annual Total Liabilities increased from Mar. 2024 (円9,470.00 Mil) to Mar. 2025 (円9,488.00 Mil) and increased from Mar. 2025 (円9,488.00 Mil) to Mar. 2026 (円29,692.00 Mil).

Takara Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Takara Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio Total Liabilities Chart

Takara Bio Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19,650.00 16,750.00 9,470.00 9,488.00 29,692.00

Takara Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,488.00 20,509.00 29,207.00 29,153.00 29,692.00
TSE:4974
50GF Score
Takara Bio Inc TSE:4974
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takara Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Takara Bio's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7786+(10776+10103
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+1027+0)
=29,692

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=133658-103966
=29,692

Takara Bio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7786+(10776+10103
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+1027+0)
=29,692

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=133658-103966
=29,692

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of 円29,692 Mil mean?
Takara Bio (TSE:4974) has a Total Liabilities of 円29,692 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Takara Bio and its competitors.
Is Takara Bio's Total Liabilities too high?
Takara Bio's current Total Liabilities is 円29,692 Mil. Overall, Takara Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Total Liabilities compare to VRTX and REGN?
Takara Bio's Total Liabilities of 円29,692 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Takara Bio and its competitors. Takara Bio's current Total Liabilities is 円29,692 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (TSE:4974) is currently considered Significantly Overvalued. The stock's GF Value™ is 円862.14, compared to a current price of 円1,144.00 — trading 32.7% above its estimated fair value. The current Total Liabilities is 円29,692 Mil. Takara Bio's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Takara Bio (TSE:4974), the current Total Liabilities is 円29,692 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takara Bio (TSE:4974) Overvalued in 2026?

Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued. The current stock price of 円1,144.00 is trading 32.7% above its estimated GF Value™ of 円862.14. GuruFocus considers Takara Bio to be Significantly Overvalued.

Key valuation signals for TSE:4974:

  • Total Liabilities: 円29,692 Mil
  • GF Value™: 円862.14 vs. price of 円1,144.00 (32.7% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TSE:4974 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takara Bio Business Description

Other Exchanges TF2:Germany
Address Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
50GF Score

Get the complete analysis for TSE:4974

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,144.00
Price
円862.14
GF Value